<DOC>
	<DOC>NCT01291108</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of AGN-210669 ophthalmic solution compared with bimatoprost ophthalmic solution (LumiganÂ®) as monotherapy and adjunctive therapy in patients with primary open-angle glaucoma or ocular hypertension.</brief_summary>
	<brief_title>Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Diagnosis of primary openangle glaucoma or ocular hypertension in each eye Requires bilateral treatment with an IOPlowering medication Best corrected visual acuity of 20/100 or better in each eye Use of oral, intramuscular, intravenous or topical ophthalmic corticosteroids within 2 months Inability to fast for up to 10 hours Prior refractive laser surgery (eg, LASIK, radial keratectomy, photorefractive keratectomy) Intraocular surgery or IOPlowering laser surgery (eg, laser trabeculoplasty) within 6 months Current or anticipated use of artificial tears or any ocular medications aside from study medications during study Anticipated wearing of contact lenses during study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>